Vland Biotech(603739)2025-04-25 13:38Financial Performance - The company's revenue for Q1 2025 was CNY 310,197,929.93, representing an increase of 8.16% compared to CNY 286,784,227.66 in the same period last year[3] - Net profit attributable to shareholders decreased by 24.73% to CNY 9,576,827.68 from CNY 12,722,943.82 year-on-year[3] - The net profit excluding non-recurring gains and losses increased by 45.44% to CNY 5,259,509.61, driven mainly by government subsidies and reduced financial income[6] - Total operating revenue for Q1 2025 reached ¥310,197,929.93, an increase of 8.8% compared to ¥286,784,227.66 in Q1 2024[16] - Net profit for Q1 2025 was ¥16,586,362.18, a decrease of 3.4% from ¥17,162,518.08 in Q1 2024[16] - The basic earnings per share decreased by 20.00% to CNY 0.04 from CNY 0.05 in the same period last year[3] - Earnings per share for Q1 2025 were ¥0.04, down from ¥0.05 in Q1 2024[17] Cash Flow - The net cash flow from operating activities improved significantly, reaching CNY 7,617,106.76, a 156.39% increase from a negative cash flow of CNY 13,507,477.33 in the previous year[3] - The net cash flow from operating activities for Q1 2025 was ¥7,617,106.76, compared to a negative ¥13,507,477.33 in Q1 2024, indicating a significant improvement[19] - Cash inflow from operating activities totaled ¥384,525,708.67 in Q1 2025, up from ¥317,112,598.93 in Q1 2024, representing an increase of approximately 21.2%[19] - The total cash outflow from operating activities increased to ¥376,908,601.91 in Q1 2025 from ¥330,620,076.26 in Q1 2024, reflecting a rise of about 14%[19] - The net cash flow from financing activities improved to ¥66,632,426.50 in Q1 2025, compared to ¥39,280,028.59 in Q1 2024, showing an increase of about 69.9%[20] Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 3,025,202,671.63, up 1.48% from CNY 2,981,000,556.19 at the end of the previous year[4] - Total liabilities increased to ¥1,147,176,454.05 from ¥1,110,984,258.58, marking a rise of 3.2%[13] - The company reported a total asset of ¥3,025,202,671.63 as of the end of the reporting period, compared to ¥2,981,000,556.19 previously[14] Shareholder Information - The company reported a total of 19,490 common shareholders at the end of the reporting period[8] - The largest shareholder, Qingdao Kangdian Industrial Co., Ltd., holds 44.4% of the shares, totaling 112,407,400 shares[9] - Shareholders' equity attributable to shareholders increased slightly by 0.55% to CNY 1,747,247,606.63 from CNY 1,737,720,580.05[4] - The total equity attributable to shareholders rose to ¥1,747,247,606.63 from ¥1,737,720,580.05, showing a slight increase of 0.3%[13] Operational Costs and Expenses - Total operating costs for Q1 2025 were ¥293,945,014.79, up from ¥273,764,144.88 in Q1 2024, reflecting a rise of 7.4%[16] - Research and development expenses for Q1 2025 were ¥28,494,054.14, compared to ¥26,717,261.31 in Q1 2024, indicating a growth of 6.6%[16] - The company's cash flow statement for Q1 2025 indicates a focus on maintaining liquidity amid rising operational costs[18] Investment Activities - Cash flow from investment activities showed a net outflow of ¥82,838,281.86 in Q1 2025, compared to a net outflow of ¥64,984,676.57 in Q1 2024, indicating a worsening investment cash flow situation[20] - The cash inflow from investment activities in Q1 2025 was ¥242,602,714.00, a substantial increase from ¥17,749,411.51 in Q1 2024[20] - The cash outflow from investment activities rose significantly to ¥325,440,995.86 in Q1 2025 from ¥82,734,088.08 in Q1 2024, marking an increase of approximately 293%[20] Overall Trends - The company’s cash flow from operating activities has shown a positive trend, while investment activities have resulted in increased cash outflows, necessitating strategic adjustments[19][20]